Condition
IRE
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07799935Not ApplicableRecruitingPrimary
IRE After Chemotherapy for Locally Advanced Pancreatic Cancer
NCT07799922Not ApplicableRecruitingPrimary
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
NCT07795619Not ApplicableRecruitingPrimary
HCCANANO-HOPE1: IRE After Chemotherapy for Locally Advanced Unresectable Perihilar Cholangiocarcinoma
Showing all 3 trials